Multiple sclerosis. Multiple sclerosis
Conditions
Interventions
Intervention 1: The control group received placebo capsules once a day for six months. Intervention 2: Supplementation group received nanocurcumin capsules containing 80 mg nanocurcumin once a day for
Sponsors
Drug Applied Research Center
Eligibility
Sex/Gender
All
Age
28 Years to 51 Years
Inclusion criteria
Inclusion criteria: Willingness to cooperate; Ranging in age from 28 to 51 years MS diagnosis by neurologist patients in relapse and remitting EDSS<5/5
Exclusion criteria
Exclusion criteria: Used nutritional supplements and antioxidants and alpha lipoic acid within a month before the study Pregnancy and lactation; History of diabetes and other chronic diseases; History of other autoimmune disease; corticosteroid use during illness; the occurrence of relapses during the study phase; acceptance rate of less than 70% of supplements; not wanting to continue cooperation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MiRNA-106b. Timepoint: Before interference and six months after interference. Method of measurement: Examined the expression levels of miRNA-106b by using Quantitative Real time PCR.;MiRNA-25. Timepoint: Before interference and six months after interference. Method of measurement: Examined the expression levels of miRNA-25 by using Quantitative Real time PCR.;MiRNA-326. Timepoint: Before interference and six months after interference. Method of measurement: Examined the expression levels of miRNA-326 by using Quantitative Real time PCR.;The frequency of Treg cells. Timepoint: Before interference and six months after interference. Method of measurement: Examined the frequency of Treg cells by using flow cytometry.;The frequency of Th17 cells. Timepoint: Before interference and six months after interference. Method of measurement: Examined the frequency of Th17 cells by using flow cytometry.;Transcription factor: Foxp3. Timepoint: Before interference and six months after interference. Method of measurement: Examined the expression levels of Foxp3 by using Quantitative Real time PCR.;Transcription factor: RoR?t. Timepoint: Before interference and six months after interference. Method of measurement: Examined the expression levels of RoR?t by using Quantitative Real time PCR.;Cytokine: TGF-ß. Timepoint: Before interference and six months after interference. Method of measurement: Examined the expression levels of TGF-ß by using Quantitative Real time PCR.;Cytokine: IL-17. Timepoint: Before interference and six months after interference. Method of measurement: Examined the expression levels of IL-17 by using Quantitative Real time PCR.;Cytokine: TGF-ß. Timepoint: Before interference and six months after interference. Method of measurement: Examined the amount of secreted cytokine TGF-ß by using sandwich ELISA method.;Cytokine: IL-17. Timepoint: Before interference and six months after interference. Method of measurement: Examined the amount of secreted cytokine IL-17 | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehdi Yousefi
Tabriz University of Medical Sciences
Outcome results
None listed